ELI LILLY & Co is 563.7x more valuable than Avidity Biosciences, Inc. by market capitalization ($1.093 T vs $1.94 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | RNA | LLY |
|---|---|---|
| Market cap | $1.94 B | $1.093 T |
| US-listed rank | #2127 | #11 |
| Revenue (latest FY) | $18.75M | $65.18B |
| Net income (latest FY) | -$684.63M | $20.64B |
| Net margin | -3650.4% | 31.7% |
| P/E (trailing FY) | - | 53.0 |
| SEC filings | 547 | 989 |
ELI LILLY & Co is 563.7x more valuable than Avidity Biosciences, Inc. by market capitalization ($1.093 T vs $1.94 B).
In their latest fiscal years, Avidity Biosciences, Inc. reported $18.75M in revenue while ELI LILLY & Co reported $65.18B.
Full pages: Avidity Biosciences, Inc. and ELI LILLY & Co, or browse the full rankings.